Kythera Biopharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 83   

Articles published

KYTH 74.93 -0.16 (-0.21%)
price chart
Why Kythera Biopharmaceuticals, Inc. Stock Soared Today
What: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) shot up by 22% today after the company agreed to sell itself to Botox-maker Allergan (NYSE:AGN) for $75 per share, or $2.1 billion.
Allergan buying Westlake Village-based Kythera Biopharmaceuticals Inc.  Pacific Coast Business Times
Botox Owner Allergan to Buy Maker of Double-Chin Treatment  Wall Street Journal
Kythera Biopharmaceuticals Inc (KYTH) Files Form 4 Insider Selling : Camille D ...
Kythera Biopharmaceuticals Inc (KYTH): Camille D Samuels , director of Kythera Biopharmaceuticals Inc sold 250 shares on Jul 1, 2015.
Morgan & Morgan Announces the Investigation of KYTHERA ...
NEW YORK, June 19, 2015 /PRNewswire/ -- Morgan & Morgan announces that it is investigating potential claims against the board of directors of KYTHERA Biopharmaceuticals, Inc. ("KYTHERA" or the "Company") (NASDAQ: KYTH) concerning the proposed ...
Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) is going to be acquired by ...  Inside Trade
KYTHERA Biopharmaceuticals Announces US Availability of KYBELLA(TM ...  CNNMoney
Kythera Biopharmaceuticals Inc (KYTH) Files Form 4 Insider Selling : John W ...
Kythera Biopharmaceuticals Inc (KYTH): John W Smither , Chief Financial Officer of Kythera Biopharmaceuticals Inc sold 4,600 shares on Jun 25, 2015.
Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) Stock Rating Downgraded at ...  OctaFinance.com
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) Given a $63.666 Price Target ...  Markets Daily
The Insider, John Smither Sold 4600 Shares of Kythera Biopharmaceuticals Inc ...
John Smither - a smart insider in Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) 75.15 -0.53 -0.70% who's presently the Chief Financial Officer - unloaded 4,600 shares of Kythera Biopharmaceuticals Inc, valued by the market at about USD$ 347,300 ...
Kythera Biopharmaceuticals Inc (KYTH) Files Form 4 Insider Selling : Iii ...  Insider Trading Report
Demand is crazy for drug that melts away double chin fat  New York Post
Analyst Price Target Update on Kythera Biopharmaceuticals, Inc.
Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH): The mean estimate for the short term price target for Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH) stands at $68.33 according to 3 Analysts. The higher price target estimate for the stock has been ...
Brokerages Expect Kythera Biopharmaceuticals to Post ($1.10) Earnings Per ...  sleekmoney
Why Kythera Biopharmaceuticals, Inc Rocketed Higher
What's happening: Shares of Kythera Biopharmaceuticals (NASDAQ:KYTH) soared higher by as much as 20% ahead of a key FDA advisory panel committee meeting next week.
FDA Panel Backs Drug that Reduces Double Chin  Newsmax
Why Keith Leonard Unloaded 3500 Shares of Kythera Biopharmaceuticals Inc ...
In view of the deal Keith Leonard made he is in the bear's eye today. The President & CEO of Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) 74.96 -0.42 -0.56% and an insider, made a sale of 3,500 shares worth $175,151 USD. The average price was ...
Kythera Biopharmaceuticals Inc (KYTH) Insider Keith R Leonard Sells 3500 ...  News Watch International
Notable Session Mover: Kythera Biopharmaceuticals, Inc. (NASDAQ:KYTH)  Vanguard Tribune
KYTHERA BIOPHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former ...
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Kythera Biopharmaceuticals, Inc. (“Kythera”) ...
KYTHERA Biopharmaceuticals Inc. Stockholders Encouraged to Contact ...
NEW YORK, June 18, 2015 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating the board of KYTHERA Biopharmaceuticals Inc. KYTH, +0.95% in connection with a buyout for only $75.00 per share. Concerned KYTH investors are ...